314 related articles for article (PubMed ID: 33517237)
21. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
22. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
[TBL] [Abstract][Full Text] [Related]
23. Precision Medicine in Tissue Engineering on Bone.
Zhao B; Peng Q; Zhou R; Liu H; Qi S; Wang R
Methods Mol Biol; 2020; 2204():207-215. PubMed ID: 32710327
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma.
Wang G; Shen N; Cheng L; Lin J; Li K
Tumour Biol; 2015 Sep; 36(10):7891-5. PubMed ID: 25953260
[TBL] [Abstract][Full Text] [Related]
25. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
26. Research progress on advanced renal cell carcinoma.
Song XD; Tian YN; Li H; Liu B; Zhang AL; Hong Y
J Int Med Res; 2020 Jun; 48(6):300060520924265. PubMed ID: 32529862
[TBL] [Abstract][Full Text] [Related]
27. Progress and opportunities for immune therapeutics in osteosarcoma.
Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
[TBL] [Abstract][Full Text] [Related]
28. MAFB Promotes Cancer Stemness and Tumorigenesis in Osteosarcoma through a Sox9-Mediated Positive Feedback Loop.
Chen Y; Wang T; Huang M; Liu Q; Hu C; Wang B; Han D; Chen C; Zhang J; Li Z; Liu C; Lei W; Chang Y; Wu M; Xiang D; Chen Y; Wang R; Huang W; Lei Z; Chu X
Cancer Res; 2020 Jun; 80(12):2472-2483. PubMed ID: 32234710
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
30. TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma.
Liang T; Chen J; Xu G; Zhang Z; Xue J; Zeng H; Jiang J; Chen T; Qin Z; Li H; Ye Z; Nie Y; Liu C; Zhan X
Sci Rep; 2021 Sep; 11(1):19315. PubMed ID: 34588497
[TBL] [Abstract][Full Text] [Related]
31. Introduction by the Guest Editor: The Rapidly Evolving Treatment Landscape of Prostate Cancer-The Convergence of Treatment Paradigms of Localized and Metastatic Diseases.
Spratt DE
Cancer J; 2020; 26(1):1. PubMed ID: 31977378
[No Abstract] [Full Text] [Related]
32. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
33. Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo.
Qiao S; Qi K; Liu C; Xu C; Ma J; Xu X; Li C; Wang Z
J Clin Lab Anal; 2020 May; 34(5):e23164. PubMed ID: 31893577
[TBL] [Abstract][Full Text] [Related]
34. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
Lilienthal I; Herold N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
[TBL] [Abstract][Full Text] [Related]
35. Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.
Scott MC; Temiz NA; Sarver AE; LaRue RS; Rathe SK; Varshney J; Wolf NK; Moriarity BS; O'Brien TD; Spector LG; Largaespada DA; Modiano JF; Subramanian S; Sarver AL
Cancer Res; 2018 Jan; 78(2):326-337. PubMed ID: 29066513
[TBL] [Abstract][Full Text] [Related]
36. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.
Hill KE; Kelly AD; Kuijjer ML; Barry W; Rattani A; Garbutt CC; Kissick H; Janeway K; Perez-Atayde A; Goldsmith J; Gebhardt MC; Arredouani MS; Cote G; Hornicek F; Choy E; Duan Z; Quackenbush J; Haibe-Kains B; Spentzos D
J Hematol Oncol; 2017 May; 10(1):107. PubMed ID: 28506242
[TBL] [Abstract][Full Text] [Related]
37. Poor survival for osteosarcoma of the pelvis: a report from the Children's Oncology Group.
Isakoff MS; Barkauskas DA; Ebb D; Morris C; Letson GD
Clin Orthop Relat Res; 2012 Jul; 470(7):2007-13. PubMed ID: 22354612
[TBL] [Abstract][Full Text] [Related]
38. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.
Li Z; Dou P; Liu T; He S
Cell Physiol Biochem; 2017; 42(4):1407-1419. PubMed ID: 28715796
[TBL] [Abstract][Full Text] [Related]
39. Advances in Osteosarcoma.
Panez-Toro I; Muñoz-García J; Vargas-Franco JW; Renodon-Cornière A; Heymann MF; Lézot F; Heymann D
Curr Osteoporos Rep; 2023 Aug; 21(4):330-343. PubMed ID: 37329384
[TBL] [Abstract][Full Text] [Related]
40. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival.
Yang J; Yang D; Cogdell D; Du X; Li H; Pang Y; Sun Y; Hu L; Sun B; Trent J; Chen K; Zhang W
Technol Cancer Res Treat; 2010 Apr; 9(2):161-9. PubMed ID: 20218738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
